Selank

• Short community courserecommended

  Community practice, not from a label or trial: within the 100-500 mcg/day subcutaneous range, with a 10-14 day clinical-style course length.

• Longer, upper-range community course

  Community practice, not from a label or trial: top of the 100-500 mcg/day subcutaneous range, for a 2-4 week course.

• Russian clinical-study range per Outliyr (not a label): roughly 400-900 mcg/day intranasal over short courses.
• Community practice, not from a label or trial: intranasal 250-900 mcg/day split across 1-2 uses; some start at 100-250 mcg.
• Community practice, not from a label or trial: subcutaneous 100-500 mcg/day. The source says this route has no Western clinical range and was not used in the main anxiety comparator trials.
• Oral use is not recommended (Outliyr).

Route: Intranasal is the studied and marketed route. Reconstituting a lyophilized vial for subcutaneous injection (or nasal use) is community use, not from a label or trial.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Bacteriostatic water per community practice; no sourced volume. The water in the protocols is arithmetic for a readable draw (5 mg vial + 2 mL gives 250 mcg = 10 units), not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

Courses in the source run from 10-14 days to 2-4 weeks; no sourced rest period.

Why:

• The sources do not state an off-cycle.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
• Combined effects with alcohol, benzodiazepines, sedatives or psychiatric medicines are under-studied (Outliyr).

Approved only in Russia (GAD and neurasthenia, nasal). Not FDA-, EMA- or MHRA-approved; not on the US 503A bulks list per Superpower; WADA S0 per Outliyr. Online vials have no quality oversight.

Common side effects:

• Reported: nasal irritation, fatigue, headache, emotional flattening, paradoxical agitation (Outliyr; community reports, not trial data).

Stop and call your prescriber if:

• Paradoxical anxiety or agitation
• Nasal irritation or signs of infection
• Injection-site infection

Labs and monitoring:

• Baseline morning cortisol (expected to fall during use) and hs-CRP (expected stable), per Outliyr.

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• Th1/Th2 cytokine balance (serum)Reported changeSmall human study

  Shifted in patients with generalised anxiety disorder and neurasthenia after 14 days of Selank; in vitro, IL-6 expression was suppressed in blood from depressed patients only. The abstract gives no figures.

  PubMed 18577961: Immunomodulatory effects of selank in anxiety-asthenic disorders

• PubMed 18454096: selank vs medazepam in GAD and neurasthenia (Zozulia 2008)
• Outliyr Selank report (formulation, community doses, regulatory status)
• Superpower Selank guide (Russian approval, route, US status)